KNSA Kiniksa Pharmaceuticals Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: KNSA

Price (delayed)

$17.88

Market cap

$1.27B

P/E Ratio

149

Dividend/share

N/A

EPS

$0.12

Enterprise value

$1.14B

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of ...

Highlights
Kiniksa Pharmaceuticals's revenue has increased by 28% YoY and by 12% QoQ
KNSA's gross profit is up by 26% year-on-year and by 12% since the previous quarter
The debt has surged by 116% year-on-year
The EPS has dropped by 96% year-on-year and by 40% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kiniksa.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KNSA
Market
Shares outstanding
70.94M
Market cap
$1.27B
Enterprise value
$1.14B
Valuations
Price to earnings (P/E)
149
Price to book (P/B)
2.92
Price to sales (P/S)
4.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.78
Earnings
Revenue
$301.77M
EBIT
-$21.56M
EBITDA
-$16.36M
Free cash flow
$21.37M
Per share
EPS
$0.12
Free cash flow per share
$0.3
Book value per share
$6.12
Revenue per share
$4.27
TBVPS
$7.12
Balance sheet
Total assets
$519.67M
Total liabilities
$87.78M
Debt
$12.14M
Equity
$431.9M
Working capital
$206.38M
Liquidity
Debt to equity
0.03
Current ratio
4.21
Quick ratio
3.57
Net debt/EBITDA
7.88
Margins
EBITDA margin
-5.4%
Gross margin
87.8%
Net margin
2.9%
Operating margin
-10.1%
Efficiency
Return on assets
1.7%
Return on equity
2.1%
Return on invested capital
-6.7%
Return on capital employed
-4.7%
Return on sales
-7.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KNSA stock price

How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
1.53%
1 week
5.74%
1 month
-10.47%
1 year
60.36%
YTD
1.94%
QTD
-9.38%

Financial performance

How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$301.77M
Gross profit
$264.82M
Operating income
-$30.54M
Net income
$8.65M
Gross margin
87.8%
Net margin
2.9%
The net margin has dropped by 97% year-on-year and by 44% since the previous quarter
KNSA's net income has dropped by 96% year-on-year and by 39% since the previous quarter
Kiniksa Pharmaceuticals's revenue has increased by 28% YoY and by 12% QoQ
KNSA's gross profit is up by 26% year-on-year and by 12% since the previous quarter

Growth

What is Kiniksa Pharmaceuticals's growth rate over time

Valuation

What is Kiniksa Pharmaceuticals stock price valuation
KNSA P/E details
P/E
149
P/B
2.92
P/S
4.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.78
The EPS has dropped by 96% year-on-year and by 40% since the previous quarter
KNSA's price to book (P/B) is 14% lower than its 5-year quarterly average of 3.4
Kiniksa Pharmaceuticals's equity has increased by 11% YoY
Kiniksa Pharmaceuticals's revenue has increased by 28% YoY and by 12% QoQ
The stock's price to sales (P/S) is 4.8% less than its last 4 quarters average of 4.4

Efficiency

How efficient is Kiniksa Pharmaceuticals business performance
The return on sales has dropped by 167% year-on-year and by 15% since the previous quarter
KNSA's ROIC has plunged by 158% YoY and by 29% from the previous quarter
Kiniksa Pharmaceuticals's return on assets has shrunk by 97% YoY and by 41% QoQ
Kiniksa Pharmaceuticals's return on equity has shrunk by 96% YoY and by 38% QoQ

Dividends

What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KNSA.

Financial health

How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities has surged by 66% year-on-year
KNSA's quick ratio is down by 33% YoY
The debt is 97% smaller than the equity
The debt to equity has soared by 200% YoY
The debt has surged by 116% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.